Buy Rating Affirmed for Alumis Inc. as ESK-001 Shows Promise in Psoriasis Treatment Trials

TipRanksSep 29 20:45 ET · Ratings

Alumis Shares Are Trading Lower. The Company Presented the 28-week Open Label Extension Period Data From Its Phase 2 STRIDE Trial of ESK-001.

BenzingaSep 27 13:17 ET

Express News | Alumis Shares Are Trading Lower. The Company Presented the 28-week Open Label Extension Period Data From Its Phase 2 STRIDE Trial of ESK-001

BenzingaSep 27 13:17 ET

Alumis Reports Positive Phase 2 Data for Plaque Psoriasis Treatment Candidate

MT NewswiresSep 27 10:34 ET

Alumis Announces 28-week Data From OLE Period of Phase 2 STRIDE Trial

TipRanksSep 27 09:05 ET

Express News | Alumis: Full 52-Week Phase 2 Ole Dataset Expected 1H 2025; Phase 3 Clinical Program

ReutersSep 27 09:01 ET